pioglitazone has been researched along with Kidney Failure, Chronic in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 9.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 5.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| "To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis." | 3.72 | Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. ( Allcock, NM; Manley, HJ, 2003) |
| "This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | 2.43 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. ( Bakris, GL; Sarafidis, PA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zanchi, A | 1 |
| Tappy, L | 1 |
| Lê, KA | 1 |
| Bortolotti, M | 1 |
| Theumann, N | 1 |
| Halabi, G | 1 |
| Gauthier, T | 1 |
| Mathieu, C | 1 |
| Tremblay, S | 1 |
| Bertrand, PC | 1 |
| Burnier, M | 1 |
| Teta, D | 1 |
| Haidinger, M | 1 |
| Antlanger, M | 1 |
| Kopecky, C | 1 |
| Kovarik, JJ | 1 |
| Säemann, MD | 1 |
| Werzowa, J | 1 |
| Oei, E | 1 |
| Samad, N | 1 |
| Visser, A | 1 |
| Chowdhury, TA | 1 |
| Fan, SL | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Chen, HS | 1 |
| Manley, HJ | 1 |
| Allcock, NM | 1 |
| Sarafidis, PA | 1 |
| Bakris, GL | 1 |
| Jin, HM | 1 |
| Pan, Y | 1 |
| Schneider, CA | 1 |
| Ferrannini, E | 1 |
| Defronzo, R | 1 |
| Schernthaner, G | 1 |
| Yates, J | 1 |
| Erdmann, E | 1 |
| Nakamura, T | 1 |
| Ushiyama, C | 1 |
| Osada, S | 1 |
| Shimada, N | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals[NCT01253928] | Phase 4 | 16 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy[NCT01175486] | Phase 4 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; E | 2006 |
5 trials available for pioglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
Topics: Adipokines; Adipose Tissue; Adult; Body Composition; Cross-Over Studies; Double-Blind Method; Fastin | 2014 |
Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Topics: Acarbose; Aged; Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Th | 2016 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Femal | 2008 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperli | 2001 |
3 other studies available for pioglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Post-transplantation diabetes mellitus: evaluation of treatment strategies.
Topics: Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glo | 2015 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Fem | 2003 |